Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

Wall Street rises as investors watch stimulus, pandemic and earnings

July 27, 2020 6:42 AM EDT

By Sinéad Carew

(Reuters) - Wall Street's main indexes closed higher on Monday as investors bet on some of the market's most high-profile stocks ahead of earnings reports while they weighed progress in U.S. government stimulus efforts against rising U.S. COVID-19 cases.

Apple Inc (NASDAQ: AAPL), Amazon.com Inc (NASDAQ: AMZN), Facebook Inc (NASDAQ: FB) and Alphabet Inc (NASDAQ: GOOGL), all due to report earnings this week, were among the top boosters of... More

Moderna (MRNA) Reports $472M Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

July 27, 2020 5:51 AM EDT

Moderna, Inc. (NASDAQ: MRNA) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Companys mRNA vaccine candidate (mRNA-1273) against COVID-19.

An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug... More

Moderna (MRNA) IV into BARDA additional $472M commitment

July 27, 2020 5:27 AM EDT

Moderna (NASDAQ: MRNA) Moderna (NASDAQ: MRNA) July weekly call option implied volatility is at 97, August is at 102; compared to its 52-week range of 51 to 172 into Biomedical Advanced Research and Development Authority, or BARDA, making an additional commitment... More

Moderna (MRNA) is not aware of any significant intellectual property impediments for any products it intends to commercialize, including mRNA-1273

July 24, 2020 3:54 PM EDT

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today released a statement on the July 23rd U.S. Patent Trial and Appeal Board (PTAB)... More

EU seeks to buy potential COVID-19 vaccines below $40 - Reuters

July 24, 2020 9:46 AM EDT

EU seeks to buy potential COVID-19 vaccines below $40 - Reuters

EU not interested in buying vaccines through WHO-led global alliance.... More

Pre-Open Stock Movers 07/24: (ABUS) (SKX) (AMD) Higher; (EHTH) (INTC) (TSLA) Lower (more...)

July 24, 2020 9:30 AM EDT

Pre-Open Stock Movers:

Arbutus Biopharma Corporation (NASDAQ: ABUS) 28.6% HIGHER; adds to Thursday's 120% surge which was related to a patent win against Moderna.

eHealth (NASDAQ: EHTH) 23.7% LOWER; reported Q2 EPS of $0.07, $0.21 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $88.8 million versus the consensus estimate of $80.78 million. eHealth sees FY2020 EPS of $3.83-$4.32, versus the consensus of $3.82. eHealth sees FY2020 revenue of $630-670 million, versus the consensus of $639.48 million.

Clearfield, Inc. (NASDAQ:... More

Arbutus Biopharma (ABUS) Confirms PTAB Decision in Moderna's (MRNA) Patent Challenge

July 24, 2020 6:08 AM EDT

Arbutus Biopharma (NASDAQ: ABUS) disclosed:

On July 23, 2020 the United States Patent and Trademark Office before the Patent Trial and Appeal Board ("PTAB") announced their decision in Moderna Therapeutics, Inc.'s challenge of the validity of U.S. Patent 8,058,069 ("the '069 Patent"). In this decision the PTAB determined no... More

After-Hours Movers 07/23: (BJRI) (MAT) (AMD) Higher; (EHTH) (INTC) (SWKS) Lower (more...)

July 23, 2020 5:59 PM EDT

After-Hours Movers:

eHealth (NASDAQ: EHTH) 23.7% LOWER; reported Q2 EPS of $0.07, $0.21 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $88.8 million versus the consensus estimate of $80.78 million. eHealth sees FY2020 EPS of $3.83-$4.32, versus the consensus of $3.82. eHealth sees FY2020 revenue of $630-670 million, versus the consensus of $639.48 million.

Clearfield, Inc. (NASDAQ: CLFD) 21.5% HIGHER; Record Revenue Driven by 48% Increase in Multiple System Operator Revenue, 22% Increase in Community Broadband Revenue and 19% Increase in Tier 1 Revenue... More

Arbutus Biopharma (ABUS) Surges on Moderna (MRNA) Patent Win

July 23, 2020 2:29 PM EDT

Arbutus Biopharma (NASDAQ: ABUS) surges after winning IPR patent challenge over Moderna (NASDAQ: MRNA). Shares last up 56%.

... More

Moderna (MRNA) Loses Challenge to Arbutus Patent for Gene Therapy Tech - Bloomberg

July 23, 2020 2:19 PM EDT

Moderna (NASDAQ: MRNA) Loses Challenge to Arbutus (NASDAQ: ABUS) Patent for Gene Therapy Tech - Bloomberg

... More

SVB Leerink Starts Moderna (MRNA) at Market Perform

July 23, 2020 7:20 AM EDT

SVB Leerink initiates coverage on Moderna (NASDAQ: MRNA) with a Market Perform rating and a price target of $65.00.

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $82.55 yesterday.

... More

U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot

July 23, 2020 7:04 AM EDT

By Carl O'Donnell

(Reuters) - The U.S. government has set a benchmark for COVID-19 vaccine pricing in a $2 billion deal announced on Wednesday with Pfizer Inc (NYSE: PFE) and German biotech BioNTech SE that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.

The deal, which is contingent on an approvable product, secures enough vaccine to inoculate 50 million Americans for about $40 a person, or about the cost of annual flu shots, and is the first to provide a direct window into likely pricing of successful COVID-19... More